FDA Implements Broad Label Change, Adding Warning for All Testosterone Products

The FDA is requiring a broad new warning to all labels for prescription testosterone products on the risks associated with abuse of anabolic androgenic steroids.

Prescription testosterone products are only approved by FDA as a hormone replacement therapy for men who have low testosterone due to certain medical conditions, genetic problems or damage to the testicles from chemotherapy or infection.